Cabaletta Bio Statistics
Total Valuation
Cabaletta Bio has a market cap or net worth of $562.54 million. The enterprise value is $509.86 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cabaletta Bio has 163.05 million shares outstanding. The number of shares has increased by 90.89% in one year.
| Current Share Class | 163.05M |
| Shares Outstanding | 163.05M |
| Shares Change (YoY) | +90.89% |
| Shares Change (QoQ) | +6.90% |
| Owned by Insiders (%) | 1.01% |
| Owned by Institutions (%) | 40.71% |
| Float | 142.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.97 |
| P/TBV Ratio | 5.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.95, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.95 |
| Quick Ratio | 2.81 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -76.47 |
Financial Efficiency
Return on equity (ROE) is -156.03% and return on invested capital (ROIC) is -80.06%.
| Return on Equity (ROE) | -156.03% |
| Return on Assets (ROA) | -71.58% |
| Return on Invested Capital (ROIC) | -80.06% |
| Return on Capital Employed (ROCE) | -168.23% |
| Weighted Average Cost of Capital (WACC) | 21.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.11M |
| Employee Count | 158 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +66.99% in the last 52 weeks. The beta is 3.23, so Cabaletta Bio's price volatility has been higher than the market average.
| Beta (5Y) | 3.23 |
| 52-Week Price Change | +66.99% |
| 50-Day Moving Average | 3.30 |
| 200-Day Moving Average | 2.67 |
| Relative Strength Index (RSI) | 47.32 |
| Average Volume (20 Days) | 3,814,439 |
Short Selling Information
The latest short interest is 22.84 million, so 14.01% of the outstanding shares have been sold short.
| Short Interest | 22.84M |
| Short Previous Month | 20.63M |
| Short % of Shares Out | 14.01% |
| Short % of Float | 15.99% |
| Short Ratio (days to cover) | 5.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -179.40M |
| Pretax Income | -175.43M |
| Net Income | -175.43M |
| EBITDA | -177.90M |
| EBIT | -179.40M |
| Earnings Per Share (EPS) | -$1.84 |
Full Income StatementBalance Sheet
The company has $116.64 million in cash and $26.45 million in debt, with a net cash position of $90.19 million or $0.55 per share.
| Cash & Cash Equivalents | 116.64M |
| Total Debt | 26.45M |
| Net Cash | 90.19M |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | 103.31M |
| Book Value Per Share | 0.93 |
| Working Capital | 80.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$142.84 million and capital expenditures -$444,000, giving a free cash flow of -$143.28 million.
| Operating Cash Flow | -142.84M |
| Capital Expenditures | -444,000 |
| Depreciation & Amortization | 1.50M |
| Net Borrowing | -9.98M |
| Free Cash Flow | -143.28M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cabaletta Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -90.89% |
| Shareholder Yield | -90.89% |
| Earnings Yield | -29.24% |
| FCF Yield | -23.88% |
Analyst Forecast
The average price target for Cabaletta Bio is $13.38, which is 287.83% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.38 |
| Price Target Difference | 287.83% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
